INTEGRUM Aktie

 

Mölndal, 5 March 2026 – Integrum (publ) today publishes its interim report for the third quarter 2025/26. During the quarter, the structural transformation was completed and the company now enters the next phase with focus on execution, growth and improved profitability. +----------------------------+--------------------------+ |Third quarter 2025/26 |1 May 2025 – 31 January | |(November – January) |2026 | | |(9 months) | |Net sales amounted to SEK | | |20,2 (23,7) million...

Mölndal, Sweden – March 3, 2026 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a live webcast presentation of its third quarter 2025/26 results on Thursday, March 5, 2026, at 10:00 CET. CEO Martin Hillsten will present the report together with CFO Louise Wåhlin. Participants will have the opportunity to ask questions during the webcast. The webcast can be accessed at: https://www.finwire.tv/webcast/integrum/q3-2025/ The report will be available at: https://integrum.se/investor-relations/financial-reports-calendar/...

Mölndal, Sweden, February 11, 2026 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company is implementing organizational changes to accelerate the commercialization of OPRA® Implant System and streamline its global production and supply chain. The changes are being made within the framework of the strategy presented in 2025. In connection with this, Jeff Zanni, President US, is leaving the company. At the same time, Dr Rickard Brånemark takes on the role as Chief Medical and Scientific Officer on a consulting basis, with responsibility for leading...

Integrum AB (publ) ("Integrum" or the "Company") announced on October 16, 2025 that the Board of Directors had resolved to carry out an issue of shares of series B with preferential right for existing shareholders of up to approximately SEK 42.7 million (the "Rights Issue"). The Board of Directors' resolution on the Rights Issue was approved at the extraordinary general meeting of the Company held on November 10, 2025. Integrum hereby announces that subscription by exercise of and through application of subscription without subscription rights amount to 18,711,946 shares, corresponding to...

Second Quarter 2025/26 (August – October) · Net sales amounted to SEK 22.3 (21.8) million. · Operating result totalled SEK -11.1 (-11.3) million. · Profit/loss after tax amounted to SEK -7.4 (-8.9) million. · Earnings per share amounted to SEK -0.35 (-0.46) · Cash flow totalled SEK -19.4 (-12.0) million. 1 May 2025 – 31 October 2025 (6 months) · Net sales amounted to SEK 46.1 (40.2) million. · Operating result totalled SEK -23.6 (-23.3) million. · Profit/loss after tax amounted to SEK -17.4 (-18.4) million. · Earnings per share amounted to SEK -0.82 (-0.95)...

Mölndal, Sweden – November 19, 2025 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2025/26 results on November 21, 2025 at 10:00 CET. Integrum's CEO Martin Hillsten will present the report together with CFO Louise Wåhlin in a webcast. The presentation will be held in English. Time: Friday, November 21, 2025 at 10:00 CET. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and presentation material will be accessible...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES. November 17, 2025, was the first day of the subscription period in Integrum AB's ("Integrum" or the "Company") rights issue of shares of series B that was resolved by the Board of Directors on...

Integrum AB (publ) ("Integrum" or the "Company") (Nasdaq First North Growth Market) publishes information document relating to the rights issue of shares of approximately SEK 42.6 million before deduction of issue costs, which was resolved by the Board of Directors on October 16, 2025, and approved by the extraordinary general meeting on November 10, 2025 (the “Rights Issue”). Information document In connection with the Rights Issue, the Company has prepared an information document (the “Information Document”) in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European...

Mölndal, 13 November 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), today publishes, in connection with the ongoing rights issue, preliminary and unaudited financial key figures for the second quarter (August–October 2025) ahead of the interim report scheduled for publication on 21 November 2025. Preliminary financial results, Q2 2025/26 (Aug–Oct 2025) · Net sales: SEK 22.3 million (21.8), an increase of 2.6%. · Operating result (EBIT): SEK -11.1 million (-11.3). · Result after tax: SEK -7.4 million (-8.9). · Earnings per share: SEK -0.35 (-0.46). ·...

Integrum AB (publ) (“Integrum” or the “Company”) has today entered into an agreement for a bridge loan of up to SEK 7 million with Buntel AB. The purpose of the loan is to cover the Company's short-term working capital needs during the period until the completion of the rights issue, resolved by the Company's extraordinary general meeting on November 10, 2025 (the “Rights Issue”). In order to cover the Company's short-term working capital needs until the proceeds from the Rights Issue are received by the Company, the Company has entered into an agreement regarding a bridge loan of up to SEK...

Mölndal, Sweden, October 23, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announced a strategic organizational restructuring to accelerate the commercialization of OPRA™ Implant System and improve operational efficiency. As part of this process, the company has initiated the statutory consultation required under Swedish employment law regarding a proposed reduction of six positions, which accounts for about 20 percent of its current workforce in Sweden. This restructuring supports the strategic shift announced by Integrum in February 2025 and reflects the...

Mölndal, Sweden, October 20, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) notes that, in statement 2025:45 dated October 17, 2025, the Swedish Securities Council (Aktiemarknadsnämnden) declared that the bidder OsteoCentric violated the takeover rules and thus acted contrary to good practice in the securities market by failing to take sufficient measures to work toward satisfaction of the completion condition requiring at least 90 percent acceptance. The Council directs serious criticism at the bidder. The Council emphasizes that the obligation to work toward the...

The Board of Directors of Integrum AB (publ) (“Integrum” or the “Company”) has today resolved to carry out a share issue of approximately SEK 42.6 million before deduction of issue costs with preferential rights for existing shareholders (the “Rights Issue”). Integrum is currently undergoing a transformative journey, from a development-driven company to a streamlined and commercially focused organization. The new strategic direction, which was presented in February 2025, aims to accelerate commercialization through a targeted go-to-market model built around Centers of Excellence. Since the...

Mölndal, Sweden, October 16, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today provides an operational update. Following the recent non-completed bid process, Integrum is taking all necessary steps to secure the company's sustainable growth. The company makes steady progress in its efforts to transform from its historical R&D focus to a more commercially oriented company. Whereas sales to date indicate that the total number of surgeries for the second quarter is likely to be in line with last year's level, the ongoing intensified marketing efforts targeting selected...

Strong global investor demand underscores confidence in Integrum's differentiated strategy and partnership-driven approach NEW YORK, Oct. 14, 2025 /PRNewswire/ -- Integrum Holdings LP ("Integrum") announced the final close of Integrum Capital Partners II LP ("Fund II") with $2.5 billion......

Mölndal, Sweden, September 18[th], 2025  - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B).  Reference is made to Integrum's press release published 17 September 2025 at 00:30 CEST, in which Integrum stated it would return to the market as new information becomes available. Today, Integrum can report the following. Correction regarding acceptance forms and VP account numbers On the contrary to the press release on 17 September 2025 at 00:30 CEST, it has been established that the two acceptance forms submitted by Integrum's founder and largest shareholder, Dr. Rickard...

Mölndal, Sweden, September 17[th], 2025  - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) comments on OsteoCentric's announcement of outcome in the public offer. September 16, 2025 at 07:00 CEST, OsteoCentric announced that approximately 69.4 percent of the shares in Integrum had been tendered and that the offer will not be completed as the 90 percent acceptance condition was not satisfied. Integrum disagrees with OsteoCentric's conclusion that the acceptance condition was not satisfied and wishes to further clarify its position on this matter. As previously announced in...

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of shareholders in Australia, Hong Kong, Japan, Canada, New Zealand, the United States or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares in the Offer would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. On 22...

MÖLNDAL, Sweden, Sept. 4, 2025 /PRNewswire/ -- Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, announced the rollout of a new global marketing strategy at the American Orthotic & Prosthetic Association's (AOPA) National Assembly in......

MÖLNDAL, Sweden, Sept. 1, 2025 /PRNewswire/ -- When publishing the interim report for the company, it was discovered that some of the total sums in the income statement show the wrong amounts. The sum of Net Sales and Work Performed by Own Use and Activated has mistakenly included Other......